Dupixent (dupilumab)

Stories

Sanofi pays Regeneron $1 billion upfront to expand Dupixent alliance

As of October 2026: Sanofi and Regeneron's blockbuster; key US patent expires 2031

Sanofi's biggest product is running out of room. Dupixent, the anti-inflammation antibody it co-developed with Regeneron, brought in $17.8 billion in 2025—roughly 36% of the French company's sales—and a key US patent expires in 2031.

Updated Oct 3